Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?
AERD
Aspirin desensitization
Aspirin-exacerbated respiratory disease
Benralizumab
CRSwNP
Chronic rhinosinusitis
Dupilumab
Mepolizumab
Nasal polyps
Omalizumab
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
29 Sep 2023
29 Sep 2023
Historique:
received:
05
09
2023
revised:
13
09
2023
accepted:
14
09
2023
pubmed:
2
10
2023
medline:
2
10
2023
entrez:
1
10
2023
Statut:
aheadofprint
Résumé
There has been a paradigm shift in the management of aspirin-exacerbated respiratory disease (AERD). It started in 2015 when the first biologic was Food and Drug Administration (FDA) approved for severe eosinophilic asthma. Thus, there emerged a new era in the treatment of patients with type 2-mediated airway diseases. This has led to an increasing number of options for patients, undoubtably a great thing, but has left clinicians without a clear answer for how to balance the therapies that exist for AERD, what to recommend for treatment, and how to best assess the benefits and risks of each therapy. This paper aims to explore these benefits and risks, and to provide a roadmap for future studies.
Identifiants
pubmed: 37778627
pii: S2213-2198(23)01050-4
doi: 10.1016/j.jaip.2023.09.019
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.